Form 4: Haemonetics Corp Executive Acquires Shares and Options
SEC Form 4 Filing
Maryanne Maunsell Farris, VP and Chief Accounting Officer of Haemonetics Corp, reports acquisition of shares and options.
Summary
- On May 16, 2025, Maryanne Maunsell Farris, VP, Chief Accounting Officer of Haemonetics Corp, acquired 800 shares of common stock.
- Following the transaction, Ms. Farris directly owns 1,816 shares of Haemonetics Corp.
- Ms. Farris also acquired 1,732 non-qualified stock options with an exercise price of $70.31, exercisable beginning May 16, 2026, and expiring on May 16, 2032.
- The stock options vest in annual increments of 25% beginning on the first anniversary of the grant date.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of insider transactions.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by signaling management's confidence in the company, but it is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of transaction: Acquisition of common stock and stock options |
| 05/16/2026 | First vesting date for stock options (25%) |
| 05/16/2032 | Expiration date for non-qualified stock options |
| 05/20/2025 | Date of signature for the Form 4 filing |
Keywords
Form 4, Haemonetics Corp, Insider Trading, Stock Options, Common Stock, Maryanne Maunsell Farris, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.